Abstract CT177: Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study

@inproceedings{Naing2018AbstractCE,
  title={Abstract CT177: Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study},
  author={Aung Naing and John D. Powderly and Gerald Steven Falchook and Benjamin C. Creelan and John J. Nemunaitis and Jose Lutzky and Adi Diab and Judy Sing-Zan Wang and Naomi Laing and Michelle Niewood and Xiaohua Gong and Gongfu Zhou and Manish R Patel},
  year={2018}
}
  • Aung Naing, John D. Powderly, +10 authors Manish R Patel
  • Published 2018
  • Medicine
  • Introduction: Epacadostat, a potent and highly selective oral inhibitor of the indoleamine 2,3- dioxygenase 1 (IDO1) enzyme, plus durvalumab, an anti-PD-L1 antibody, is being studied in patients with advanced solid tumors (NCT02318277). Phase 1 preliminary safety data for the overall population and efficacy data for patients with advanced pancreatic cancer (PC) are reported as of 29 Oct 2017 data cutoff.Methods: Adult patients with PC, melanoma, NSCLC, or SCCHN were enrolled in the 3+3 dose… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv